BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

StemCyte, Inc. Relocates California Operations to 36,000-Square-Foot Facility in Covina


5/12/2008 7:14:59 AM

COVINA, Calif., May 12 /PRNewswire/ -- StemCyte Inc. today announced that it has relocated its California operations from Arcadia to a 36,000-square- foot facility in Covina.

The new facility will provide StemCyte with increased storage capacity for its supply of plasma-depleted umbilical cord blood (UCB) stem cell products. In addition, the Covina facility will house StemCyte executives and researchers.

Our UCB stem cell products are already being used to treat patients with over 35 different diseases in 32 different countries," said Kenneth J. Giacin, chairman and chief executive officer of StemCyte. "The new Covina facility is an integral part of our plan to build the largest, most diverse supply of UCB stem cell products to ensure we are able to treat even more patients."

In addition to Covina, StemCyte's operations are located in New Jersey and Taiwan. The company is also developing StemCyte India Therapeutics in Ahmedabad in collaboration with Apollo Hospitals and Cadila Pharmaceuticals.

About StemCyte Inc.

StemCyte Inc. is a global cell therapy company with a focus on umbilical cord blood (UCB) stem cells. Since 2001, the company's stem cell products have been used to successfully treat more than 600 patients suffering from life-threatening diseases and conditions. StemCyte also has a leadership position in the development of new cell therapies in high-growth areas with the greatest clinical need. The company is accredited by AABB (formerly the American Association of Blood Banks) and Foundation for the Accreditation of Cellular Therapy (FACT). For more information, visit www.stemcyte.com.

CONTACT: Ian Stone, +1-619-814-3510, ian.stone@russopartnersllc.com, or
David Schull, +1-212-845-4271, david.schull@russopartnersllc.com, both of
Russo Partners LLC, for StemCyte Inc.

Web site: http://www.stemcyte.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES